Global ERA Drugs Market Growth 2024-2030

Global ERA Drugs Market Growth 2024-2030

ERAs (Endothelin Receptor Antagonists) are a class of drugs used to treat certain cardiovascular and pulmonary diseases. They work by blocking the binding of endothelin (a powerful vasoconstrictor) to its receptors, thereby relaxing blood vessels, lowering blood pressure, and improving blood flow.

The global ERA Drugs market size is projected to grow from US$ 2739 million in 2024 to US$ 5238 million in 2030; it is expected to grow at a CAGR of 11.4% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “ERA Drugs Industry Forecast” looks at past sales and reviews total world ERA Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected ERA Drugs sales for 2024 through 2030. With ERA Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world ERA Drugs industry.

This Insight Report provides a comprehensive analysis of the global ERA Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on ERA Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global ERA Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for ERA Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global ERA Drugs.

United States market for ERA Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for ERA Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for ERA Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key ERA Drugs players cover Johnson & Johnson, Zhengda Tianqing, Sinotherapeutics, Qilu Pharmaceutical, Hangzhou Zhongmei Huadong Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of ERA Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Bosentan
Ambrisentan
Macitentan

Segmentation by Application:
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Zhengda Tianqing
Sinotherapeutics
Qilu Pharmaceutical
Hangzhou Zhongmei Huadong Pharmaceutical
Shanghai Xudong Haipu Pharmaceutical
Shanghai Pharmaceutical Group
Jiangsu Yunyang Group Pharmaceutical
Mylan
Teva
Dr. Reddy's Laboratories
Gilead Sciences
United Therapeutics

Key Questions Addressed in this Report

What is the 10-year outlook for the global ERA Drugs market?

What factors are driving ERA Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do ERA Drugs market opportunities vary by end market size?

How does ERA Drugs break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver. Show more